Avantogen’s Hawaii Biotech Inc. receives clinical trial support from Walter Reed Army Institute of Research
Avantogen Ltd announced additional support for the Dengue vaccine program developed by Hawaii Biotech Inc, in which Avantogen holds a significant investment stake. The Dengue clinical trial will be conducted as part of a broader trial at the clinical trials centre of the US Walter Reed Army Institute of Research (WRAIR). This institution has a well recognised competency in emerging infectious disease and considerable experience with dengue fever, according to the company.
Avantogen believes that a partnership with a reputable organisation such as WRAIR gives further validation of the Hawaii Biotech Inc vaccine technology platform and the actual dengue vaccine candidate that has been developed. Furthermore, Avantogen (and Hawaii Biotech Inc) have also gained a potential partner to accelerate the program. Next steps could be the dosage of first subjects with the proprietary, recombinant-DNA-based vaccine candidate being developed by Hawaii Biotech Inc.
Organizations
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.